Uveitis Clinical Trial
Official title:
Peptide B27PD (Optiquel®) as Corticosteroid-sparing Therapy for Chronic Non-infectious Uveitis (BOOTS)
Verified date | December 2014 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
Uveitis is a serious inflammatory condition in which the body's immune system attacks parts
of the eye, often causing vision loss. Uveitis treatments involve various drugs that suppress
the immune system, but these medicines sometimes do not work or may cause serious side
effects. Researchers are interested in developing new treatments for uveitis that are more
effective and have fewer side effects.
Optiquel® is an experimental medication being tested for its effectiveness against uveitis.
It contains B27PD, a small protein fragment, which is similar to proteins in the parts of the
eye being attacked by the immune system. Taking Optiquel® (B27PD) by mouth may induce oral
tolerance, in which the immune system is taught to recognize and not attack normal parts of
the human body.
Objectives:
To evaluate the safety and effectiveness of B27PD (Optiquel®) as a treatment for uveitis.
Eligibility:
Individuals at least 18 years of age who have had noninfectious uveitis in one or both eyes
for at least 3 months, have vision of 20/200 or better in at least one eye, and are taking
daily prednisone or an equivalent medication.
Design:
Participants will be screened with a physical examination, medical history, blood and urine
tests, and an eye exam.
This study will last a maximum of 52 weeks. During the first 12 weeks of the study,
participants will have a study visit every 2 weeks. For the remainder of the study,
participants will have a study visit every 4 weeks.
Participants will have frequent blood and urine tests, and will also have eye examinations
and special procedures (fluorescein angiography and indocyanine green angiography) to
evaluate the effectiveness of the treatment.
Participants will be randomly assigned into one of three groups and will receive either one
of two different doses of B27PD or a placebo. During the study, participants will also have
their dose of prednisone or other steroid medication reduced.
Participants will take one capsule three times per week on Monday, Wednesday, and Friday, for
a total of 24 weeks. Participants may take the capsule with water, but should not consume any
other drinks or any kind of food until at least 30 minutes have passed to prevent stomach
upset. The capsules should be stored in the refrigerator.
Status | Completed |
Enrollment | 31 |
Est. completion date | February 2014 |
Est. primary completion date | November 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
INCLUSION CRITERIA: - Participant must be 18 years of age or older. - Participant must be able to understand the informed consent process and sign the informed consent form. - Participant has been diagnosed with non-infectious unilateral or bilateral uveitis for at least three months. Participants who were diagnosed more than a year prior to enrollment must have had a recurrence in ocular inflammation within the past year. - Participant must be receiving a current treatment with prednisone between 20 to 40 mg/day (or an equipotent dose of an alternative corticosteroid). Participants who are on a regimen of no more than one anti-metabolite inhibitor at the time of randomization (e.g., azathioprine, methotrexate, mycophenolate) in addition to the prednisone may be enrolled and are allowed to continue the anti-metabolite. - The participant's uveitis must be controlled in eligible eyes, quiescent eyes [anterior chamber cells and vitreous haze Standardization of Uveitis Nomenclature (SUN) grade of 0]. - The participant's eligible eye(s) is able to be evaluated for activity of disease both biomicroscopically and ophthalmoscopically. - The participant's baseline intraocular pressure must be > 5 mmHg and = to 30 mmHg in both eyes. Concurrent use of intraocular pressure-lowering medication and/or prior glaucoma surgery is acceptable. - Participant has best-corrected distance visual acuity in the better seeing eye of 20/200 or better [= 34 Early Treatment Diabetic Retinopathy Study (ETDRS) letters]. - Female participants of childbearing potential must not be pregnant or lactating and must be willing to undergo serum pregnancy tests throughout the study. - Women of childbearing potential must agree to use reliable methods of contraception while receiving the study medication and for 6 weeks following the last administration. Acceptable methods of contraception include hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods with spermicide (diaphragm with spermicide, condom with spermicide) or surgical sterilization (hysterectomy, tubal ligation or partner with vasectomy). EXCLUSION CRITERIA: - Participant has a non-iatrogenic immunodeficiency state [e.g., Human Immunodeficiency Virus (HIV) infection or congenital immunodeficiency]. - Participant had intraocular surgery or intraocular injection within three months prior to randomization. - Participant is expected to have an elective ocular surgery or intraocular injection during the study period. - Participant is using systemic corticosteroid therapy for a non-ocular disease or non-ocular organ involvement. - Participant has a history or diagnosis of Behcet's disease. - Participant has a clinically suspected and/or confirmed central nervous system or ocular lymphoma. - Participant has an active systemic infectious disease or malignancy that requires treatment. - Participant has a known chronic disease or condition of the gastrointestinal system that may interfere wih the absorption of the investigational product as determined by the investigator (e.g., active hepatitis, chronic diarrhea, inflammatory bowel disease, Crohn's disease, ulcerative colitis, celiac disease, diverticulosis or diverticulitis). - Participant has two or more food allergies. - Participant has an implant containing anti-inflammatory, immunosuppressive or antiviral drugs, unless a period 50% longer than the anticipated duration of effect of the implant has elapsed. - Participant received periocular corticosteroid injections within 4 months prior to randomization or is expected to need periocular corticosteroid injections during the study duration. - Participant received treatment with infliximab, etanercept, adalimumab, interferon, cyclosporine, tacrolimus, sirolimus, within two weeks prior to randomization. - Participant received cytotoxic therapy (e.g., cyclophosphamide) within six months prior to randomization. - Participants for whom, in the physician's opinion, any of the protocol procedures may pose a special risk not outweighed by the potential benefits of participating in the study. - Participant who is unlikely to comply with the study protocol or who is likely to be moving or lost to follow-up. - Participant who is currently enrolled or has been participating in any other investigative therapeutic clinical trial during the three months prior to randomization. - Participant has a known need for a colonoscopy or surgery of the gastrointestinal tract during the study. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Eye Institute (NEI) | The EMMES Corporation |
United States,
Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M, Fletcher MJ, Chasan-Taber S, Finger E, Morales A, Le CH, Trentham DE. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 1998 Feb;41(2):290-7. Erratum in: Arthritis Rheum 1998 May;41(5):938. — View Citation
Dandona L, Dandona R, John RK, McCarty CA, Rao GN. Population based assessment of uveitis in an urban population in southern India. Br J Ophthalmol. 2000 Jul;84(7):706-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Primary Outcome is the Time to Recurrence of Uveitis in Participants of Each Treatment Group, During or After Tapering of Oral Prednisone to a Dose of 7.5 mg/Day, or Equipotent Dose of Alternative Corticosteroid Medication. | Recurrence (or flare) is defined as an anterior chamber cells and/or vitreous haze grading of = 2+ using the Standardization of Uveitis Nomenclature (SUN) grading system. The time to this event is defined as the time from randomization to recurrence, loss to follow-up or end of study, whichever comes first. Participants that do not present with disease recurrence will be censored at the time of the last disease evaluation. |
Time from randomization to recurrence, loss to follow-up, or end of study, up to 52 weeks | |
Secondary | Proportion of Participants Determined to be a Treatment Failure, Defined as Recurrent (or Flare) of Uveitis or a Drop in Visual Acuity of = 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters | Recurrent (or flare) of uveitis is defined as at least a 2-step increase in anterior chamber cells and/or vitreous haze using the Standardization of Uveitis Nomenclature (SUN) grading system | Week 24 | |
Secondary | Proportion of Participants Determined to be a Treatment Failure, Defined as Recurrent (or Flare) of Uveitis or a Drop in Visual Acuity of = 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters | Recurrent (or flare) of uveitis is defined as at least a 2-step increase in anterior chamber cells and/or vitreous haze using the Standardization of Uveitis Nomenclature (SUN) grading system | Week 52 | |
Secondary | Mean Change in Best-Corrected Visual Acuity (BCVA) in Right Eye (OD) at Week 24 Compared to Baseline | Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. | Baseline and Week 24 | |
Secondary | Mean Change in Best-Corrected Visual Acuity (BCVA) in Left Eye (OS) at Week 24 Compared to Baseline | Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. | Baseline and Week 24 | |
Secondary | Number of Participants Presenting No Change in Retinal Vessel Leakage Observed by Fluorescein Angiography (FA) at Week 24 Compared to Baseline | Week 24 | ||
Secondary | Number of Participants Presenting No Change in Autofluorescence Patterns as Observed on Fundus Autofluorescence (FAF) at Week 24 Compared to Baseline | Week 24 | ||
Secondary | Reduction in Exposure to Corticosteroid as Measured by the Area Under the Dose-time Curve. | This outcome was not analyzed as no data was collected at Week 24. | Week 24 | |
Secondary | Changes in High-speed Indocyanine Green Angiography (HS-ICG) | Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Active, not recruiting |
NCT04704609 -
Imaging Quantification of Inflammation (IQI)
|
||
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Withdrawn |
NCT01280669 -
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
|
Phase 2 | |
Terminated |
NCT02907814 -
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
|
N/A | |
Active, not recruiting |
NCT02252328 -
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT04183387 -
Simvastatin in Uveitis
|
Phase 2 | |
Completed |
NCT01983488 -
Clinical Outcome in Uveitis
|
||
Withdrawn |
NCT00499551 -
A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis
|
Phase 1/Phase 2 | |
Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
Completed |
NCT00132691 -
Multicenter Uveitis Steroid Treatment (MUST) Trial
|
Phase 4 | |
Terminated |
NCT00114062 -
Study to Treat Uveitis Associated Macular Edema
|
Phase 2 | |
Completed |
NCT00001867 -
Effect of Pregnancy on Uveitis
|
N/A | |
Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
Active, not recruiting |
NCT03828019 -
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
|
Phase 3 | |
Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 | |
Active, not recruiting |
NCT03889860 -
Objective Choroidal Thickness Measurements in Uveitis
|
||
Completed |
NCT00070759 -
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
|
Phase 2 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Active, not recruiting |
NCT05385757 -
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
|